Lately, Applied has taken over Celera's original business, selling gene-sequence subscriptions to drug companies, while Celera focuses on developing its own products.
One roadblock to synthbio's future is the messed-up patent environment in biotech, where every tiny protein pathway and genesequence has an owner wanting to get paid.